169 related articles for article (PubMed ID: 31432686)
1. The prevalence of
He Y; Sun LY; Gong R; Liu Q; Long YK; Liu F; Wang F
Biomark Med; 2019 Aug; 13(12):1035-1044. PubMed ID: 31432686
[TBL] [Abstract][Full Text] [Related]
2. Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays.
Li T; Maus MK; Desai SJ; Beckett LA; Stephens C; Huang E; Hsiang J; Zeger G; Danenberg KD; Astrow SH; Gandara DR
J Thorac Oncol; 2014 Jan; 9(1):18-25. PubMed ID: 24346090
[TBL] [Abstract][Full Text] [Related]
3. Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer.
Tao H; Shi L; Zhou A; Li H; Gai F; Huang Z; Che N; Liu Z
Lung Cancer; 2020 Nov; 149():154-161. PubMed ID: 33017727
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
5. Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.
Zhang SS; Nagasaka M; Zhu VW; Ou SI
Lung Cancer; 2021 Aug; 158():126-136. PubMed ID: 34175504
[TBL] [Abstract][Full Text] [Related]
6. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.
Lin E; Li L; Guan Y; Soriano R; Rivers CS; Mohan S; Pandita A; Tang J; Modrusan Z
Mol Cancer Res; 2009 Sep; 7(9):1466-76. PubMed ID: 19737969
[TBL] [Abstract][Full Text] [Related]
7. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
[TBL] [Abstract][Full Text] [Related]
8. Detecting ALK Rearrangement with RT-PCR: A Reliable Approach Compared with Next-Generation Sequencing in Patients with NSCLC.
Kuang Y; Xu P; Wang J; Zheng Y; Sun X; Li Z; Gan R; Li H; Guo Y; Yao F; Zhu C; Ke Z; Tang K
Mol Diagn Ther; 2021 Jul; 25(4):487-494. PubMed ID: 34133003
[TBL] [Abstract][Full Text] [Related]
9. Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant.
To KF; Tong JH; Yeung KS; Lung RW; Law PP; Chau SL; Kang W; Tong CY; Chow C; Chan AW; Leung LK; Mok TS
J Thorac Oncol; 2013 Jul; 8(7):883-91. PubMed ID: 23625156
[TBL] [Abstract][Full Text] [Related]
10. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.
Martelli MP; Sozzi G; Hernandez L; Pettirossi V; Navarro A; Conte D; Gasparini P; Perrone F; Modena P; Pastorino U; Carbone A; Fabbri A; Sidoni A; Nakamura S; Gambacorta M; Fernández PL; Ramirez J; Chan JK; Grigioni WF; Campo E; Pileri SA; Falini B
Am J Pathol; 2009 Feb; 174(2):661-70. PubMed ID: 19147828
[TBL] [Abstract][Full Text] [Related]
11. CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.
Zhang M; Wang Q; Ding Y; Wang G; Chu Y; He X; Wu X; Shao YW; Lu K
J Thorac Oncol; 2018 Nov; 13(11):1792-1797. PubMed ID: 30010043
[TBL] [Abstract][Full Text] [Related]
12. Correlation of anaplastic lymphoma kinase overexpression and the EML4-ALK fusion gene in non-small cell lung cancer by immunohistochemical study.
Chen TD; Chang IC; Liu HP; Wu YC; Wang CL; Chen YT; Chen YR; Huang SF
Chang Gung Med J; 2012; 35(4):309-17. PubMed ID: 22913857
[TBL] [Abstract][Full Text] [Related]
13. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
[TBL] [Abstract][Full Text] [Related]
14. A novel mass spectrometry-based assay for diagnosis of EML4-ALK-positive non-small cell lung cancer.
Sakai K; Okamoto I; Takezawa K; Hirashima T; Kaneda H; Takeda M; Matsumoto K; Kimura H; Fujita Y; Nakagawa K; Arao T; Nishio K
J Thorac Oncol; 2012 May; 7(5):913-8. PubMed ID: 22722791
[TBL] [Abstract][Full Text] [Related]
15. Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants.
Li Y; Zhang T; Zhang J; Li W; Yuan P; Xing P; Zhang Z; Chuai S; Li J; Ying J
Lung Cancer; 2018 Apr; 118():128-133. PubMed ID: 29571990
[TBL] [Abstract][Full Text] [Related]
16. Detection of EML4-ALK fusion genes in a few cancer cells from transbronchial cytological specimens utilizing immediate cytology during bronchoscopy.
Kanaji N; Bandoh S; Ishii T; Tadokoro A; Watanabe N; Takahama T; Haba R; Imataki O; Dobashi H; Matsunaga T
Lung Cancer; 2012 Aug; 77(2):293-8. PubMed ID: 22494566
[TBL] [Abstract][Full Text] [Related]
17. The role of immunohistochemical analysis in the evaluation of EML4-ALK gene rearrangement in lung cancer.
Sullivan HC; Fisher KE; Hoffa AL; Wang J; Saxe D; Siddiqui MT; Cohen C
Appl Immunohistochem Mol Morphol; 2015 Apr; 23(4):239-44. PubMed ID: 25265433
[TBL] [Abstract][Full Text] [Related]
18. Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer.
Mano H
Cancer Sci; 2008 Dec; 99(12):2349-55. PubMed ID: 19032370
[TBL] [Abstract][Full Text] [Related]
19. Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing.
Moskalev EA; Frohnauer J; Merkelbach-Bruse S; Schildhaus HU; Dimmler A; Schubert T; Boltze C; König H; Fuchs F; Sirbu H; Rieker RJ; Agaimy A; Hartmann A; Haller F
Lung Cancer; 2014 Jun; 84(3):215-21. PubMed ID: 24674157
[TBL] [Abstract][Full Text] [Related]
20. A novel EML4-ALK variant: exon 6 of EML4 fused to exon 19 of ALK.
Penzel R; Schirmacher P; Warth A
J Thorac Oncol; 2012 Jul; 7(7):1198-9. PubMed ID: 22706607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
